Life Science Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Life Science Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pompe Disease
Company files for European approval of Myozyme for Pompe disease
January 25th, 2005
Genzyme Corp. (GENZ) announced that the European Medicines Evaluation Agency (EMEA) has accepted its marketing authorization application for Myozyme (alglucosidase alfa), an investigational enzyme replacement therapy for Pompe disease.
If approved, Myozyme would become the first treatment available to patients with Pompe disease, a debilitating and often fatal muscle disorder resulting from an inherited enzyme deficiency.
The EMEA's Committee for Human Medicinal Products is expected to issue an opinion on the Myozyme application within 1 year, and a decision by the European Commission is anticipated early in 2006.
...
Source: Life Science Weekly (2005-01-25)
|
|
|
